AlleyCorp Closes $335M Fund II as Kevin Ryan Redefines Venture
TL;DR
AlleyCorp has closed its second institutional fund at $335 million, up from the $250 million debut vehicle it raised in 2024 when Kevin Ryan's firm took outside capital for the first time after 17 years as a family office. The firm is doubling down on the earliest stages — Ryan caps most first checks under $10 million — across healthcare, deep tech, and general technology, with eight unicorns already in the portfolio. The more interesting story is Ryan's argument that the nine- and ten-figure AI rounds dominating the market are not venture capital at all.
Key Takeaways
A 34% step-up is the tell, not the headline. $250 million to $335 million is a deliberate, modest increase in a year when US venture deployment hit $412.7 billion and peers doubled or tripled fund sizes. Ryan is explicit that he would consider $500-600 million eventually, but only to add verticals or geographies — not to change check size. That is a firm sizing to strategy rather than to market conditions.
The incubation DNA is the differentiator, and it predates the fund. AlleyCorp is not a conventional seed fund that happens to incubate. Ryan co-founded MongoDB, Business Insider, Gilt Groupe, and Zola, many of them started inside the firm. When Ryan says "we need to help them build that business," he is describing a company-formation shop with a fund attached, which is a fundamentally different product from a seed fund with a platform team.
Ryan's "that's not venture capital" line is a real market call, not a soundbite. His argument is that the tens of billions flowing into Anthropic, OpenAI, and SpaceX are late-stage growth capital wearing a VC costume, and that stripping those out would reveal genuine venture dollars are flat or falling. If he is right, the entire "record venture year" narrative is a composition error — and a lot of LPs are benchmarking against a distorted denominator.
Deep tech has quietly become a primary vertical. Valar Atomics achieved criticality under the DOE's Reactor Pilot Program and became the first US nuclear startup to produce power from an advanced reactor. Portal Space Systems and Radical AI round out an energy, space, and industrial-systems book that would have looked eccentric for a New York internet firm five years ago and now looks prescient.
Fund Overview
Fund Name: AlleyCorp Fund II
Fund Size: $335 million (up from the $250 million debut institutional fund in 2024)
Stage: Pre-seed and seed, including in-house incubation
Check Size: First checks generally under $10 million
Geography: New York-centred, with team members in the US and UK
Focus: Healthcare, deep tech, and diversified technology
Key LPs: Not disclosed
Why This Fund Matters
AlleyCorp is one of the few firms in the market whose structure genuinely resists the gravity of the current cycle, and it is worth understanding why. A firm that starts companies cannot deploy $2 billion no matter how much LPs offer, because the constraint is founders in the building, not dollars in the account. Ryan's fund size is downstream of a physical limit. That gives his restraint a credibility that most "we're staying disciplined" messaging lacks.
The substantive claim Ryan is making deserves more attention than it has received. His position is that a company like DoubleClick — which he took to 1,500 employees and a $1.1 billion sale in 2005 — would today stay private for a decade and IPO at $10 billion, and that Anthropic-scale private rounds are structurally public-market investments. The implication is that the industry's headline numbers are measuring two entirely different asset classes and reporting the sum. For LPs building venture allocations off aggregate deployment data, that is not a semantic quibble. It means the denominator is broken.
His counter-example is the more persuasive part: an investment last week at a $25 million valuation into a company with $500,000 of revenue. That is what early-stage venture actually looks like, and the economics of it have barely moved while the headlines have gone vertical. If Ryan is right that VC dollars could appear to drop once the megadeals normalise, firms that never inflated will look like they grew.
There is a New York dimension too. The AlleyCorp Building in Nolita, opened in June, now houses portfolio companies and other firms including Benchstrength and BBG Ventures. Ryan has spent two decades building physical and social infrastructure for NYC tech, and a fund is only one instrument in that. Deep Tech New York, Digital Health New York, and the DOC longevity conference are sourcing infrastructure as much as they are events. That flywheel is not replicable with capital alone.
The Team
Kevin Ryan is Founder and CEO. Former CEO of DoubleClick, co-founder of MongoDB, Business Insider, Gilt Groupe, and Zola, and co-founder of Transcend Therapeutics, the psychedelic-adjacent drug maker that sold in June for $1.2 billion — a bet he made after reversing his own scepticism on the category. He founded AlleyCorp as a family office in 2007.
Per the firm's own team page, AlleyCorp's General Partners today are Jay Hass (General Partner & CFO), Marshall Porter, Alexi Nazem, MD, and Abe Murray. The wider partnership includes Susannah Shipton (Partner), Florencia Herra Vega (Partner & CTO, and CEO of Toboggan Labs), Michelle Garland (Partner, and CEO at Soul Search), and Sercan Ozcan (Partner, Finance & Operations). Doug Band and David Rosenthal, MD are Venture Partners — not GPs. The principal bench includes Brannon Jones (quantum and photonics), Omar Njie, MD, Jane Suh, and Luc Ryan-Schreiber. Note that several third-party investor databases still list a partner roster that does not match the firm's current page; we have used AlleyCorp's own listing.
A source familiar with the firm's financials told Fortune that AlleyCorp's previous investments have generated an all-time 60% IRR. We would treat that as publicly reported rather than independently verified — it is a single anonymous source and an unusually strong number.
Early Portfolio
Eight unicorns currently sit in the portfolio, including Rogo (raised $160 million Series D led by Kleiner Perkins at a $2 billion valuation; 250+ financial institutions using its agentic AI), ShopMy, Valar Atomics, and Thyme Care (CNBC Disruptor 50, working with 120,000+ cancer patients). Recent Q2 activity: AlleyCorp co-led Vanna Health's $17 million round, led Queue's $12.6 million seed for autonomous robotic pharmacy, led Clarasight's $11.5 million Series A, and co-led Pathway Labs' $8.5 million seed alongside Breyer Capital. Pearl Health raised $100 million led by Andreessen Horowitz with AlleyCorp participating, and now manages roughly $3.6 billion in annualised medical spend.
What This Means for Founders
If you are pre-seed or seed in healthcare, deep tech, or applied AI, and you want investors who will roll up their sleeves on company building rather than governance, AlleyCorp is close to a perfect fit — and the $25 million post-money at $500k revenue deal proves they still write those checks at those prices. The physician network around Alexi Nazem, Omar Njie, and the Doctorpreneurs programming is a genuine unfair advantage for healthcare founders specifically. The engineering practice and the building itself are real assets, not decoration.
Be clear-eyed about the trade. This is an incubation-first firm, and incubation-first firms have opinions. If your company was started in AlleyCorp's orbit, expect deep involvement. If you are a fully formed team looking for a passive check and a light touch, the value proposition inverts. Also note the geographic gravity: this is a New York firm with a New York network, and the network is a large fraction of what you are buying.
Fund Momentum Take
Ryan is running the correct strategy for a company builder and saying the quiet part out loud about everyone else's. The $335 million is exactly the right size for what AlleyCorp does — big enough to lead seeds and reserve for follow-ons, small enough that a $50 million exit still moves the needle. The willingness to name the AI megaround as a different asset class is the most useful thing any GP has said publicly this quarter, because it gives LPs a framework for the discomfort they have all been feeling about the aggregate numbers.
The risks are real and they cluster around key-person dependency. AlleyCorp is Kevin Ryan's judgment institutionalised, and its edge — knowing which non-obvious bet will be obvious in five years, as with psychedelics in 2018 — does not obviously transfer to a bench. The firm has built out GPs across healthcare, deep tech, and diversified technology, which is the right response, but Fund II will be the first real test of whether the sourcing engine outperforms with Ryan as an allocator rather than an operator. The reported 60% all-time IRR, if accurate, also sets a bar that a $335 million fund in a compressed-entry-price environment will find hard to clear.
Our bet: AlleyCorp Fund II outperforms the median 2026 vintage precisely because it is not competing in the auction that is destroying returns elsewhere. When your companies do not exist until you help start them, there is no price discovery to lose. The deep tech pivot is the bet we would watch most closely — Valar Atomics producing power from an advanced reactor is the kind of result that either validates the whole vertical or turns out to be the exception that flatters it. We think Ryan gets more of these right than the base rate suggests, and we would rather own the concentrated version of that judgment than a diversified index of it.
Frequently Asked Questions
How big is AlleyCorp Fund II?
$335 million, up from the $250 million debut institutional fund raised in 2024. AlleyCorp operated as Kevin Ryan's family office from 2007 until it took outside capital for the first time in 2024.
What check sizes does AlleyCorp write?
Ryan says he is devoted to first checks under $10 million and to backing young companies. He recently invested at a $25 million valuation into a company with $500,000 in revenue — a useful marker of where the firm actually plays.
Who are AlleyCorp's General Partners?
Per the firm's own team page: Jay Hass (also CFO), Marshall Porter, Alexi Nazem MD, and Abe Murray. Kevin Ryan is Founder & CEO. Doug Band and David Rosenthal MD are Venture Partners, and several others hold Partner titles without the GP designation.
What does AlleyCorp invest in?
Healthcare, deep tech, and diversified technology. The deep tech book spans energy, space, industrial systems, and infrastructure — Valar Atomics, Portal Space Systems, and Radical AI are representative.
Will AlleyCorp raise a bigger fund next time?
Ryan says it could be $500-600 million, but that he would use the extra capital to add verticals — a dedicated biotech practice, for instance — or geographies, rather than to write larger checks. He defines venture by check size and stage, not fund size.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.